Publicaciones en colaboración con investigadores/as de Hospital de Cruces (39)

2024

  1. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis

    The European respiratory journal, Vol. 61, Núm. 3

  3. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  4. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

2022

  1. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level

    Current Urology Reports, Vol. 23, Núm. 6, pp. 93-97

  2. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  3. Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units

    Archivos de Bronconeumologia, Vol. 58, pp. 22-31

  4. Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study

    The Lancet Regional Health - Europe, Vol. 18

  5. Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic

    Cancers

2021

  1. (Pro)renin receptor is a novel independent prognostic marker in invasive urothelial carcinoma of the bladder

    Cancers, Vol. 13, Núm. 22

  2. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  3. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

  4. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments

    Cancers, Vol. 13, Núm. 9

2020

  1. Altered tissue and plasma levels of fibroblast activation protein-α (FAP) in renal tumours

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

    Current Urology Reports, Vol. 20, Núm. 1

  2. Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology

    npj Precision Oncology, Vol. 3, Núm. 1

  3. Precise immunodetection of PTEN protein in human neoplasia

    Cold Spring Harbor Perspectives in Medicine, Vol. 9, Núm. 12

  4. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder

    Human Pathology, Vol. 91, pp. 61-68

2018

  1. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 27-30